Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 538

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Open access
Jones, Stephen E., Savin, Michael A., Holmes, Frankie Ann, O'Shaughnessy, Joyce A., Blum, Joanne L., Vukelja, Svetislava, McIntyre, Kristi J., Pippen, John E., Bordelon, James H., Kirby, Robert, Sandbach, John, Hyman, William J., Khandelwal, Pankaj, Negron, Angel G., Richards, Donald A., Anthony, Stephen P., Mennel, Robert G., Boehm, Kristi A., Meyer, Walter G., Asmar, Lina·2006·Journal of Clinical Oncology
DOI 10.1200/jco.2006.06.5391
Open this paper in CoChat — free account

Abstract

Purpose: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS). Patients and Methods: Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. Between June 1997 and December 1999, 1,016 patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m 2, respectively; n = 510) or TC (75 and 600 mg/m 2, respectively; n = 506), administered intravenously every 3 weeks as adjuvant chemotherapy. Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor–positive disease, were administered after completion of chemotherapy. Results: Both treatment groups (TC and AC) were well balanced with respect to major prognostic factors. Patients were observed through 2005 for a median of 5.5 years. At 5 years, DFS rate was significantly superior for TC compared with AC (86% v 80%, respectively; hazard ratio [HR] = 0.67; 95% CI, 0.50 to 0.94; P = .015). Overall survival rates for TC and AC were 90% and 87%, respectively (HR = 0.76; 95% CI, 0.52 to 1.1; P = .13). More myalgia, arthralgia, edema, and febrile neutropenia occurred on the TC arm; more nausea and vomiting occurred on the AC arm as well as one incident of congestive heart failure. Conclusion: At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.06.5391

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 538

Metadata

Authors
Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R., Sandbach, J., Hyman, W. J., Khandelwal, P., Negron, A. G., Richards, D. A., Anthony, S. P., Mennel, R. G., Boehm, K. A., Meyer, W. G., & Asmar, L.
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2006-12-01
Volume
24
Issue
34
Pages
5381-5387
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2006.06.5391
OpenAlex
W2115432999
Cited by
538
References
13
FWCI
15.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2006.06.5391
The paper
Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R., Sandbach, J., Hyman, W. J., Khandelwal, P., Negron, A. G., Richards, D. A., Anthony, S. P., Mennel, R. G., Boehm, K. A., Meyer, W. G., & Asmar, L. (2006). Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.06.5391

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.